IVI will convene a series of webinars in 2021 to communicate research findings, explore new methodologies in value assessment, and host public dialogue on relevant issues. Join IVI for open conversations about best practices with researchers, patient organizations, policymakers, and those who pay for care.

Upcoming Events

SAVE THE DATE: Health Equity and Value Assessment

Date: Thursday, April 22, 2021
Time: 1:00 PM EST

Inequities in health care access and outcomes across different subgroups have been widely documented. As suitable frameworks for value assessment in the U.S. setting are being developed, approaches to addressing health inequities must be part of the conversation.

Join us in April for this important discussion. Stay tuned for more details!

Recent Events

Principles for Good Value Assessment

Date: Thursday, February 25, 2021
Time: 2:00 PM EST

In December, IVI dubbed 2021 “the year of the patient”: advancing the conversation and practice of patient-centered value assessment in tangible ways. The patient voice is crucial in achieving the promise of value assessment to improve care, achieve better outcomes, and lower costs.

In this webinar, dialogue with IVI and patient advocates about patient-centricity in action and learn more about activities for the year ahead. IVI’s new Principles for Value Assessment in the U.S. was discussed, along with their practical application for patients, employers, and researchers.

Alan Balch, PhD
Alan Balch, PhDPatient Advocate Foundation
Dr. Balch is the Chief Executive Officer of the Patient Advocate Foundation (PAF) and the National Patient Advocate Foundation (NPAF). Dr. Balch is a member of IVI’s Patient Advisory Council.
Jennifer Bright, MPA
Jennifer Bright, MPAInnovation and Value Initiative
Ms. Bright is the Executive Director of the Innovation and Value Initiative. She brings over two decades of healthcare policy, issue management, patient advocacy and executive leadership to this position.

Click below to view the recorded webinar.

VIEW

ISPOR-IVI Webinar Series

IVI and ISPOR collaborated, with the help from an expert advisory committee, to define and host a series of webinars highlighting key challenges confronting HEOR methodologists, patients, clinicians, and policy-makers during the COVID-19 pandemic. The webinar series explored multiple viewpoints and focused on potential pathways for solutions in international and U.S.-focused value assessment and health technology assessment (VA/HTA).

ISPOR-IVI Webinar Series (Session 5)

Using Value Assessment/Health Technology Assessment in Pursuing Innovation and Access in a Pandemic

Original Air Date: Thursday, November 12, 2020
Length: 75 minutes

This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness. Where have our usual VA/HTA approaches worked and where have they proven inadequate to the challenges presented by COVID-19? Based on our learnings throughout the series, what are the emerging needs for methods, scientific research, public health, and defining and building consensus? What are the most immediate priorities for supporting innovation and access at both US and international levels? Does value-based pricing apply in the pandemic context? How do we coordinate public and private investment in these interventions and treatments?

Learning Objectives

  • Describe how to incorporate policy and non-pharmaceutical interventions in the VA/HTA
  • Discuss how VA/HTA accounts for effect of new treatments on non-COVID related care and the long-run health and multi-sectoral impacts
  • Consider how to address public health infrastructure investment, and how to set priorities
  • Define methods that can help evaluate and prioritize policy interventions
  • Articulate the role of US and global government agencies and other stakeholders in public health investment
VIEW RECORDED WEBINAR

ISPOR-IVI Webinar Series (Session 4)

The Role of Public Health – How can VA/HTA inform pandemic policy interventions and public resource allocation?

Original Air Date: Friday, October 23, 2020
Length: 75 minutes

COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame.

Learning Objectives

  • Describe how to incorporate policy and non-pharmaceutical interventions in the VA/HTA
  • Discuss how VA/HTA accounts for effect of new treatments on non-COVID related care and the long-run health and multi-sectoral impacts
  • Consider how to address public health infrastructure investment, and how to set priorities
  • Define methods that can help evaluate and prioritize policy interventions
  • Articulate the role of US and global government agencies and other stakeholders in public health investment
VIEW RECORDED WEBINAR

ISPOR-IVI Webinar Series (Session 3)

Balancing Economics and Ethics: How Can VA/HTA Support Equitable Resource Allocation?

Original Air Date: Monday, September 21, 2020
Length: 75 minutes

Evolving data from COVID-19 tell the story we already know: the impact of this disease affects – especially people of color – disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?

After attending this webinar, participants will be able to:

  • Discuss key ethical issues in allocating limited resources in fighting against COVID-a9 in the US and globally
  • Consider how to account for vulnerable populations especially at risk, and their needs
  • Evaluate importance of equity in VA/HTA
  • Identify methods and their readiness to address equity in distribution of tests, treatments, and vaccines
VIEW RECORDED WEBINAR

ISPOR-IVI Webinar Series (Session 2)

COVID-19: Are Our Methods Up To The Task?

Original Air Date: Thursday, August 27, 2020 at 1:30pm PDT/4:30pm EDT
Length: 75 minutes

The methods, assumptions, and inputs to Value Assessment (VA) and Health Technology Assessment (HTA) are an evolving debate in the US, as we seek to balance questions of population health-driven resource allocation with the unique needs of health system, employer, payer, and societal decision-making and the emerging science of patient heterogeneity and precision medicine.

VIEW RECORDED WEBINAR

ISPOR-IVI Webinar Series (Session 1)

How Should The COVID-19 Pandemic Challenge Conventional Wisdom About VA/HTA?

Original Air Date: Wednesday, July 29, 2020 at 12:30pm EDT/9:30am PDT
Length: 60 minutes

During the COVID-19 pandemic, it is clear that our views on healthcare access, the role scientific research, and the need for global collaboration in pursuing effective and cost-effective care has been affected. The first webinar in the ISPOR-IVI joint webinar series brings together international and US thought leaders to discuss the ongoing key challenges faced by the healthcare industry in regard to health technology assessment and value assessment.

VIEW RECORDED WEBINAR

Past Events

Note: The recorded webinar is available on demand. Once you register on the event page, the webinar will be immediately available to you. You can return to the event page at any time, click on the “Already Registered” link and enter your e-mail address to view the webinar again.

Advancing the Science of Value Assessment: New Open-Source Model for Non-Small Cell Lung Cancer

Original Air Date: February 25, 2019 at 3pm EST/12pm PST
Length: 60 minutes

This webinar introduces IVI’s new open-source value model focused on EGFR+ non-small cell lung cancer (NSCLC). Released February 1, public comment on the model and user interfaces is encouraged through April 1, 2019.

In this webinar, which is designed for all audiences, IVI’s team provides an overview of the model, how it generates customized data on different non-small cell lung cancer therapies and how these data-driven insights unlock value for healthcare stakeholders.

VIEW RECORDED WEBINAR

Modernizing Models for Value Assessment: A Detailed Discussion of the Open-Source IVI-NSCLC Model

Original Air Date: February 27, 2019 at 2:30pm EST/11:30am PST
Length: 90 minutes

This webinar, which is designed for technical audiences, showcases IVI’s new open-source value model focused on EGFR+ non-small cell lung cancer (NSCLC).

IVI’s team, led by Jeroen Jansen and Devin Incerti, present an overview to foster a deeper understanding of the entirety of the IVI-NSCLC model package. The presenters will walk you through the key components of the open-source model, how the IVI model generates customized information on EGFR+ NSCLC treatment sequences, and how to apply the information in assessing value in health care among different populations.

VIEW RECORDED WEBINAR

Measuring the Value of Health Care Treatments: Time for a New Approach

Original Air Date: December 12, 2017 at 4pm EST/1pm PST
Duration: 59 minutes

While different health care stakeholders have different perceptions of value, traditional value assessments are often “black boxes” that only account for a single perspective or a single population. For that reason, existing value frameworks tend to fall short for many individual stakeholders. The Open-Source Value Platform (OSVP) seeks to change that by creating flexible, transparent, iterative, and consensus-based modeling platforms for specific diseases.

IVI has recently released its model of value assessment for rheumatoid arthritis (RA). Join IVI for a webinar to better understand how the OSVP process works, learn about our first model in rheumatoid arthritis, and find out how you can get involved.

VIEW RECORDED WEBINAR

Creating Open-Source Models for Value Assessment: A Detailed Discussion of the IVI Rheumatoid Arthritis Model

Original Air Date: December 14, 2017 at 4pm EST/1pm PST
Duration: 59 minutes

Open-Source Value Project (OSVP) models are built to be entirely open-source, allowing anyone to customize the tool depending on their own assumptions and understanding of value. IVI has released the source code, documentation, and suite of tools for its open-source model of value assessment for rheumatoid arthritis (RA) into the public domain. Our R package and highly customizable model interfaces allow experienced users to choose from over 300 different model structures, vary nearly all model inputs, and assess value using either cost-effectiveness or multi-criteria decision analytic approaches.

Are you interested in the technical and methodological aspects of the model? Join IVI for a webinar about the IVI-RA model and IVI’s open-source modeling approach. Presenters will walk you through the key components of the open-source consensus-based model, how the IVI model generates customized information on rheumatoid arthritis treatments, and how to apply the information in assessing value in health care.

VIEW RECORDED WEBINAR